Lipocomb

Ezetimibe and rosuvastatin zinc, the active ingredients in Lipocomb, are a cholesterol absorption inhibitor and an HMG‑CoA reductase inhibitor presented as oral tablets for oral use. The combination targets elevated cholesterol and mixed dyslipidaemia in adult patients requiring lipid‑lowering therapy.

GNH USA supplies Lipocomb as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. All batches are manufactured under EU GMP standards and undergo comprehensive quality testing before release. The product is exported to multiple regions, adhering to local regulatory requirements.

Lipocomb, a combination lipid‑lowering agent, is used to manage disorders of cholesterol metabolism. - Hypercholesterolemia: reduces elevated LDL‑cholesterol levels in patients with primary or secondary hypercholesterolemia. - Mixed dyslipidemia: improves the overall lipid profile by lowering LDL‑C and triglycerides while raising HDL‑C. - Primary hyperlipidaemia: provides comprehensive cholesterol control in patients with genetically or lifestyle‑induced lipid abnormalities. - Cardiovascular risk reduction: used as part of therapy to lower risk of atherosclerotic events in high‑risk patients.

Lipocomb may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Headache: mild to moderate headache reported. - Myalgia: muscle aches without significant CK elevation. - Abdominal discomfort: nausea, dyspepsia or flatulence. - Elevated liver enzymes: mild transaminase increase.

Serious or Rare Side Effects: - Rhabdomyolysis: severe muscle breakdown with marked CK rise, potentially leading to renal failure. - Severe hepatic injury: marked elevation of transaminases or jaundice. - Allergic reactions: rash, pruritus, angioedema, or anaphylaxis.

When prescribing Lipocomb, clinicians should consider several precautionary measures to ensure safe use. - Liver function monitoring: assess baseline transaminases and repeat periodically during therapy. - Renal impairment: adjust use in patients with severe renal dysfunction. - Drug interactions: review concomitant medications that affect statin metabolism. - Pregnancy and lactation: avoid use due to unknown safety profile. - Muscle symptoms: discontinue if unexplained muscle pain or weakness occurs. - Store at ambient temperature: keep below 25 °C, retain in original packaging, protect from moisture.

Lipocomb can interact with other medicines, influencing its efficacy or safety.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., clarithromycin, itraconazole): may increase rosuvastatin exposure and risk of myopathy. - Cyclosporine: markedly raises rosuvastatin levels, contraindicated. - Gemfibrozil: combined use raises risk of rhabdomyolysis. - Antacids containing aluminum or magnesium: may reduce ezetimibe absorption.

Moderate Interactions (Monitor Closely): - Warfarin: statins may potentiate anticoagulant effect, monitor INR. - Niacin: additive effect on liver enzymes, monitor hepatic function. - Fibrates (other than gemfibrozil): increased myopathy risk, monitor symptoms.